Stryker (SYK): analysis in plain words
Is Stryker cheap or expensive? How it makes money, whether it grows and its risks, explained in plain words and with its official accounts.
Stryker (SYK) is listed on the NYSE and we classify it in healthcare and pharma. Below are its key dated figures, how it makes money, how it compares with its sector, what works for and against Stryker according to those figures, and the questions people ask most about the stock. No buy or sell tips.
Stryker (SYK) key figures as of November 4, 2026
| Figure | Value | What it measures |
|---|---|---|
| Share price | $339.65 | Last price on November 4, 2026 |
| P/E ratio (TTM) | 36.2x | Price over earnings per share |
| Revenue growth | +7.6% | Latest quarter vs the same quarter a year earlier |
| Net margin (TTM) | 13.8% | Profit for every 100 of sales |
| Net debt / EBITDA | 1.6x | Years of operating profit to repay debt |
| Dividend yield | 1.13% | Annual dividend over price |
| Market cap | $129.3 billion | What the stock market values it at |
The Stryker figures come from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026. Any SYK figure that is not available shows as N/A: we do not estimate it.
How Stryker makes money
Stryker sells medical equipment to hospitals through two segments. MedSurg and Neurotechnology covers surgical instruments, emergency equipment, hospital beds and neurovascular devices, while Orthopaedics includes hip and knee implants and the Mako surgical robot. The United States is its largest market, followed by Europe and Asia.
Over the last 12 months, Stryker brought in revenue of $26.3 billion. For every 100 it sells, Stryker keeps 65.7 after the direct cost of what it sells (gross margin) and 23.0 after all operating costs (operating margin). With 56,000 full-time employees, that is about $470,000 of revenue per employee.
Stryker against its sector
To know whether a Stryker figure is high or low you have to put it next to similar companies. This table compares Stryker with the median of the 30 healthcare and pharma companies Fintols covers, with data as of November 4, 2026.
| Figure | Stryker | healthcare and pharma median |
|---|---|---|
| P/E | 36.2x | 31.3x (30) |
| Revenue growth | +7.6% | +8.3% (33) |
| Net margin | 13.8% | 14.9% (33) |
| Dividend yield | 1.13% | 1.52% (33) |
| Net debt / EBITDA | 1.6x | 1.6x (31) |
In short, against the typical healthcare and pharma company, Stryker trades on a higher P/E and pays a lower dividend yield. By size, Stryker ranks number 17 of 28 healthcare and pharma companies quoted in USD on Fintols.
The bull case for Stryker
These are the strengths in the Stryker figures as of November 4, 2026:
- Analysts expect Stryker earnings to rise: its P/E on the next 12 months of estimated earnings is 20.8x, below the current 36.2x.
- Stryker earns 16.0% a year on its shareholders' money (return on equity).
The main risk for Stryker
The Stryker figures as of November 4, 2026 show no clear red flag (no heavy debt, no losses, no falling sales). Its main risk is the one built into its business: a key drug losing patent protection or a clinical trial failing, plus government pressure on prices.
Frequently asked questions about Stryker
Is it a good time to buy Stryker stock?
Fintols does not tell you whether to buy or sell Stryker, and nobody knows what the price will do tomorrow. What we can show you is where it stands today. As of November 4, 2026, Stryker stock trades at $339.65, 13% below its 52-week high ($389.33) and 27% above its low ($267.00). Its P/E is 36.2x against a healthcare and pharma median of 31.3x, and 20.8x on the earnings analysts expect over the next 12 months. With Stryker, as with any stock, timing matters less than understanding the business, investing for the long run and not betting everything on a single company.
Does Stryker pay a dividend?
Yes. As of November 4, 2026, Stryker pays $3.52 per share a year, which at today's price is a yield of 1.13%. It uses 37% of its profit to pay it, which leaves room to keep paying it if profit dips. Its average dividend yield over the last five years is 0.99%. The healthcare and pharma median on Fintols is 1.52%.
Is Stryker stock expensive?
It depends on what you compare it with. On P/E, Stryker trades at 36.2x its last 12 months of earnings: more expensive than the healthcare and pharma median (31.3x). Including its debt, Stryker is valued at 17.4x its EBITDA (EV/EBITDA). A high P/E alone does not make Stryker expensive: it can be justified if earnings grow fast, and a low one can reflect a business in trouble.
Who are Stryker's competitors?
On Fintols we compare Stryker with Vertex, Boston Scientific and Novo Nordisk, which are also in healthcare and pharma. As of November 4, 2026, Vertex is worth $139.2 billion and trades on a P/E of 36.8; Boston Scientific is worth $66.4 billion and trades on a P/E of 19.3; Novo Nordisk is worth $186.0 billion and trades on a P/E of 10.3. Each has a side-by-side comparison with Stryker below.
Stryker competitors
- Vertex (VRTX) analysis · Stryker vs Vertex comparison
- Boston Scientific (BSX) analysis · Stryker vs Boston Scientific comparison
- Novo Nordisk (NVO) analysis · Stryker vs Novo Nordisk comparison
To understand Stryker better
- DCF and WACC Explained: A Practical Valuation Guide
- P/E Ratio and EPS Explained: How to Read Them Without Traps
More companies like Stryker: healthcare and pharma stocks and S&P 500 companies. Open the full SYK analysis with its valuation and scenarios. Educational content about Stryker, not investment advice.